Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease

@inproceedings{Geifman2017EvidenceFB,
  title={Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease},
  author={Nophar Geifman and Roberta Diaz Brinton and Richard E. Kennedy and L. S. Schneider and Atul J. Butte},
  booktitle={Alzheimer's Research & Therapy},
  year={2017}
}
Despite substantial research and development investment in Alzheimer’s disease (AD), effective therapeutics remain elusive. Significant emerging evidence has linked cholesterol, β-amyloid and AD, and several studies have shown a reduced risk for AD and dementia in populations treated with statins. However, while some clinical trials evaluating statins in general AD populations have been conducted, these resulted in no significant therapeutic benefit. By focusing on subgroups of the AD… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS
12 Citations
69 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 69 references

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

  • M Sano
  • Cochrane Database Syst Rev
  • 2011
Highly Influential
6 Excerpts

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology

  • RC Petersen
  • 2010
Highly Influential
5 Excerpts

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology

  • HH Feldman
  • Geifman et al. Alzheimer's Research & Therapy
  • 2017
1 Excerpt

A survey of current trends in computational drug repositioning

  • J Li
  • Brief Bioinform
  • 2016
2 Excerpts

Similar Papers

Loading similar papers…